LLY vs ABBV
Eli Lilly and Company vs AbbVie Inc. · Updated Nov 9, 2026
LLY — 10 winsABBV — 13 wins
Price Performance
LLY +46.11%ABBV +33.89%
Performance
| LLY | ABBV | |
|---|---|---|
| 1 Month | +16.36% | +6.68% |
| 3 Months | +10.47% | +17.20% |
| 6 Months | +43.49% | +44.20% |
| YTD | +26.64% | +27.20% |
| 1 Year | +47.00% | +34.07% |
| 3 Year | +194.95% | +103.99% |
| 5 Year | +557.37% | +153.45% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | +30.7% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
| ABBV | +27.7% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
Valuation
| LLY | ABBV | |
|---|---|---|
| P/E Ratio | 48.35 | 142.51 |
| Forward P/E | 24.06 | 20.80 |
| PEG Ratio | 1.77 | 1.23 |
| P/S Ratio | 18.35 | 8.05 |
| P/B Ratio | 42.50 | 18.38 |
| EV/EBITDA | 29.46 | 24.22 |
Financials
| LLY | ABBV | |
|---|---|---|
| EPS (TTM) | $28.15 | $2.04 |
| Gross Margin | +78.98% | +83.54% |
| Operating Margin | +46.44% | +31.56% |
| Net Margin | +37.36% | +4.66% |
| ROE | +81.01% | +13.23% |
| ROA | +21.68% | +2.67% |
| Debt/Equity | 1.39 | 2.65 |
Growth
| LLY | ABBV | |
|---|---|---|
| Revenue Growth YoY | +55.55% | +12.43% |
| Revenue Growth QoQ | +2.63% | -9.72% |
| EPS Growth YoY | +169.94% | -45.83% |
| EPS Growth QoQ | +11.77% | -61.76% |
Technical
| LLY | ABBV | |
|---|---|---|
| RSI (14) | 60.54 | 60.03 |
| % From 20-Day SMA | +4.53% | +1.46% |
| % From 50-Day SMA | +12.08% | +6.87% |
| % From 200-Day SMA | +23.77% | +21.63% |
| % From 52-Week High | -6.34% | -4.06% |
| % From 52-Week Low | +60.02% | +52.36% |
Analyst Ratings
LLY
Buy(34 analysts)
Strong SellHoldStrong Buy
Price Target
$1445.12
+6.18% upside
ABBV
Buy(46 analysts)
Strong SellHoldStrong Buy
Price Target
$308.88
+6.28% upside
Overview
| LLY | ABBV | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $1.33T | $505.40B |
| Shares Outstanding | 940.7M | 1.77B |
| Avg Volume (10D) | 3.38M | 5.76M |
| Dividend Yield | 0.47% | 2.42% |
Frequently Asked Questions
Is LLY or ABBV a better buy right now?
Based on 23 comparable metrics, ABBV leads in 13 categories while LLY leads in 10. ABBV has a consensus analyst rating with 46 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, LLY or ABBV?
Over the past year, LLY returned +47.00% compared to ABBV's +34.07%. In the short term (1 month), LLY returned +16.36% vs ABBV's +6.68%.
Is LLY or ABBV more expensive?
LLY trades at a P/E of 48.35 compared to ABBV's 142.51. On a price-to-sales basis, LLY trades at 18.35x vs ABBV's 8.05x. Forward P/E: LLY at 24.06 vs ABBV at 20.80.
Which stock has higher growth, LLY or ABBV?
LLY's revenue grew +55.55% year-over-year compared to ABBV's +12.43%. EPS growth: LLY at +169.94% vs ABBV at -45.83%.
Do LLY and ABBV pay dividends?
LLY pays a dividend with a yield of 0.47%. ABBV pays a dividend with a yield of 2.42%.
Which stock do analysts prefer, LLY or ABBV?
LLY has 34 analysts with a target price of $1445.12 (+6.18% upside). ABBV has 46 analysts with a target of $308.88 (+6.28% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.